AstraZeneca: ‘Firing On All Cylinders’ In Q3
But UK Drug Maker Warns China Growth Will Now Slow
Executive Summary
AstraZeneca beat market forecasts when posting its fifth successive quarter of revenue growth – but the UK drug maker warned that its sales in China will now slow down.
You may also be interested in...
AZ Sees China Digital Health Blossoming Post-Coronavirus
'Internet hospitals', electronic prescriptions and online physician and patient education are likely to see increasing importance in a post-coronavirus China, says AstraZeneca's emerging markets head.
Sun Allies With AZ To Drive China Oncology Push
India's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize on the UK firm’s strong position in this market.
What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot
China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.